Clinical Trials State of the Industry Report 2005: Market Forces Drive Change in Drug Development, Released by BioWorld Today
Thomson BioWorld has just published Clinical Trials State Of The IndustryReport 2005, a new report focusing on the clinical research industry.
ATLANTA GA USA -- MEDICAL INDUSTRY E-MAIL NEWS SERVICE(TM) -- MAY 18 2005 --Thomson BioWorld has just published Clinical Trials State Of The IndustryReport 2005, a new report focusing on the clinical research industry.
With content researched and collected by Thomson CenterWatch, the leading information provider for the clinical trials industry, this market research report reveals critical data and information about trends affecting the drug development and study conduct markets, both in the US and Europe.
308 PAGES OF PROPRIETARY MARKET RESEARCH:
-- Drug development spending and cycle times
-- Pharmaceutical spending
-- Clinical grants spending
-- Clinical research spending - US and worldwide
-- CRO market size, costs and performance
-- Study conduct/clinical trials markets
-- Investigative sites
The Clinical Trials State Of The Industry Report 2005 gives detailed insight into the trends and history affecting the clinical research industry. It contains more than 300 up-to-date charts and graphs, special "Year in Review" sections for 2003 and 2004, and noteworthy articles relating to:
-- Phase I spending
-- The top CROs in Europe
-- Expanding opportunities in Central and Eastern Europe
-- Physicians referring patients into clinical trials
-- CRC loss tied to heavy workload
-- And much more.
"By combining more than 300 tables and charts with expert opinions from industry thought-leaders, the Clinical Trials State of the Industry Report 2005 is an ideal resource for creating dynamic data-driven presentations, preparing business plans and marketing strategies, and deepening your understanding of the clinical trials sector," says Managing Editor Michael Harris. "If you're a biotech or pharmaceutical executive, researcher, analyst or investor with a stake in the clinical research industry, this report is for you."
MORE INFORMATION AVAILABLE ONLINE:
To view sample pages or order the Clinical Trials State Of The Industry Report 2005: Market Forces Drive Change In Drug Development, please visit: http://sacserv.com/links.jsp?linkid=20172&subid=686369&campid=141800&type=0
ABOUT THE THOMSON CORPORATION:
The Thomson Corporation, with 2004 revenues of $8.10 billion, is a global leader in providing integrated information solutions to business and professional customers.
http://sacserv.com/links.jsp?linkid=20173&subid=686369&campid=141800&type=0
Thomson provides value-added information, software tools, and applications to more than 20 million users in the fields of scientific research, healthcare, law, tax, accounting, financial services, higher education, reference information, and corporate e-learning and assessment. With operational headquarters in Stamford CT, Thomson has approximately 38,000 employees and provides services in approximately 130 countries. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).
Thomson BioWorld (a Thomson business) information solutions can be found at: http://sacserv.com/links.jsp?linkid=20174&subid=686369&campid=141800&type=0- an internationally recognized site for executives, analysts and investors following the day-to-day developments in the biotechnology, pharmaceutical and med-tech markets. Focusing on scientific business news and information, Thomson BioWorld's data-rich website provides access to daily developments in these sectors, as well as 15 years' worth of archived data, trends and company information. Key products include BioWorld Today - the newspaper of record for the biotechnology industry; BioWorld Financial Watch - a weekly monitor of biotech's financial markets; and BioWorld International - focusing on life science developments in Europe.
Thomson CenterWatch (a Thomson Business) is a leader in the clinical trials industry. With a specific focus on the clinical trials industry, CenterWatch is a Boston-based publishing and information services company that provides business journalism, reference databases, accredited training manuals, original research and analysis, and market intelligence services to assist organizations in managing and implementing clinical research strategies and operational initiatives.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
